BioSpace News Archive

Cytovale® announced that the first hospital to commercially implement the company’s IntelliSep® rapid sepsis diagnostic has now screened over 5,000 patients with the test.

NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Mr. Mike Kelly, President & CEO, will be presenting a corporate update

ImmunityBio, Inc. announced the initial treatment of multiple patients in the United States to receive therapy with ANKTIVA®, ImmunityBio’s recently approved immunotherapy for Bacillus Calmette-Guérin -unresponsive non-muscle invasive bladder cancer carcinoma in situ.

Applied DNA Sciences, Inc., a leader in PCR-based DNA technologies, and Alphazyme LLC, a Maravai LifeSciences company and global provider of specialty enzymes used in the life sciences sector, announced the successful conclusion of the companies’ previously announced Linea™ RNAP manufacturing scale-up agreement.

MCRA, the leading privately held independent medical device, diagnostics, and biologics Clinical Research Organization (CRO) and advisory firm is pleased to announce its role in the U.S. Food and Drug Administration’s (FDA) De Novo granting for Onkos Surgical’s antibacterial coating for tumor and revision orthopedic implants.

Qosina, a global supplier of OEM single-use components to the medical and pharmaceutical industries, is pleased to welcome Thomas Kapke as the new representative for the German and Benelux market.

Gemina Laboratories Ltd. is pleased to announce that it has qualified for trading on the OTCQB Venture Market in the United States operated by the OTC Markets Group Inc. and the Company’s common shares have commenced trading on the OTCQB under the symbol “GLABF.” The Company’s common shares will continue to trade on the CSE Exchange under the symbol “GLAB” and on the Frankfurt Exchange under the symbol “817".

NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies, today announced that it will present and host institutional investor meetings at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on Thursday, June 27, 2024.

CureDuchenne, a global nonprofit committed to finding and funding a cure for Duchenne muscular dystrophy, will host webinars in English and Spanish for the Duchenne community after the U.S. Food and Drug Administration approved the expansion to the label indication for ELEVIDYS from Sarepta Therapeutics to include individuals with Duchenne muscular dystrophy with a confirmed mutation in the DMD gene who are at least 4 years of age.